Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 248

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

hsa‐miR‐210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer

Gee, Harriet E., Camps, Carme, Buffa, Francesca M., Patiar, Shalini, Winter, Stuart C., Betts, Guy, Homer, Jarrod, Corbridge, Rogan, Cox, Graham, West, Catharine M. L., Ragoussis, Jiannis, Harris, Adrian L.·2010·Cancer

Abstract

BACKGROUND: Hypoxia is an important mechanism of treatment resistance in head and neck squamous cell carcinoma (HNSCC). MicroRNAs are short noncoding RNAs that regulate multiple mRNAs and are frequently dysregulated in cancer. The authors have investigated the role of 3 microRNAs, including the hypoxia‐induced hsa‐miR‐210, as potential markers of hypoxia or prognosis. METHODS: Three hypoxia‐related microRNAs, hsa‐miR‐210, hsa‐miR‐21, and hsa‐miR‐10b, were measured in 46 samples from patients with HNSCC. Expression levels were correlated with clinicopathological variables and other markers of hypoxia: a published 99‐gene hypoxia metagene, individual hypoxia‐related genes such as TWIST1, and immunohistochemical expression of hypoxia‐inducible factor 1 and its target gene carbonic anhydrase 9. We then performed survival analyses to investigate the prognostic significance of these microRNAs. RESULTS: Only the level of hsa‐miR‐210 was significantly correlated with other markers of hypoxia, including the 99‐gene hypoxia metagene (rho = 0.67, P < .001). We found no association between hsa‐miR‐210, hsa‐miR‐21, or hsa‐miR‐10b and clinicopathological variables such as tumor size, differentiation, and stage. However, high levels of hsa‐miR‐210 were associated with locoregional disease recurrence (P = .001) and short overall survival (P = .008). hsa‐miR‐21 and hsa‐miR‐10b had no prognostic significance. CONCLUSIONS: Expression of hsa‐miR‐210 in head and neck cancer correlates with other approaches for assessing hypoxia and is associated with prognosis. This warrants further study as a classification marker of patients for therapies involving modulation of hypoxia. Cancer 2010. © 2010 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.25009

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 248

Metadata

Authors
Gee, H. E., Camps, C., Buffa, F. M., Patiar, S., Winter, S. C., Betts, G., Homer, J., Corbridge, R., Cox, G., West, C. M. L., Ragoussis, J., & Harris, A. L.
Venue
Cancer
Publisher
Wiley
Published
2010-04-20
Volume
116
Issue
9
Pages
2148-2158
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1996780398
Cited by
248
References
8
FWCI
7.23
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: hsa‐miR‐210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. https://app.cochat.ai/papers/10.1002/cncr.25009
The paper
Gee, H. E., Camps, C., Buffa, F. M., Patiar, S., Winter, S. C., Betts, G., Homer, J., Corbridge, R., Cox, G., West, C. M. L., Ragoussis, J., & Harris, A. L. (2010). hsa‐miR‐210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer. https://doi.org/10.1002/cncr.25009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.